Laboratory methods in the haemostatic laboratory

Thrombosis and Haemostasis

Volumn 96, Issue 5, 2006, Pages 545-546

  Mannhalter, Christine ^a   Quehenberger, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 7A; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; ORAL CONTRACEPTIVE AGENT; PROTEIN C; THROMBIN;

ACTIVATED PROTEIN C RESISTANCE; ANTICOAGULATION; AREA UNDER THE CURVE; ASSAY; BLEEDING; BLOOD CLOTTING; CLINICAL PROTOCOL; DISEASE SEVERITY; DRUG MONITORING; EDITORIAL; HEMOPHILIA A; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; LABORATORY TEST; MORBIDITY; MORTALITY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; SCREENING; SENSITIVITY AND SPECIFICITY; THROMBIN TIME; THROMBOPHILIA; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

BLOOD COAGULATION TESTS; HEMOSTASIS; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES;

EID: 33751208615     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-10-0589     Document Type: Editorial

References (15)

1. Sorensen B, Ingerslev J. Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography. Haemophilia 2005; (Suppl 1): 1-6.
2. Hemker HC, Al Dieri R, De Smet E, et al. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 2006; 96: 553-61.
3. Dargaud Y, Trzeciak MC, Bordet JC, et al. Use of calibrated automated thrombinography ± thrombomodulin to recognise the prothrombotic phenotype. Thromb Haemost 2006; 96: 562-7.
4. Brummel-Ziedins KE, Vossen CY, Butenas S, et al. Thrombin generation profiles in deep venous thrombosis. J Thromb Haemost 2005; 3: 2497-505.
5. Hron G, Kollars M, Binder BR, et al. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. J Am Med Assoc 2006; 296: 397-402.
6. Agnelli G, Iorio A, Renga C, et al. Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases. Circulation 1995; 92: 2819-24.
7. Marcucci R, Gori AM, Giannotti F, et al. Markers of hypercoagulability and inflammation predict mortality in patients with heart failure. J Thromb Haemost 2006; 4:1017-22.
8. Ofosu FA. Review: Laboratory markers quantifying prothrombin activation and actions of thrombin in venous and arterial thrombosis do not accurately assess disease severity or the effectiveness of treatment. Thromb Haemost 2006; 96: 568-77.
9. Eickelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: Time for a fresh look. Thromb Haemost 2006; 96: 547-52.
10. Dati F, Hafner G, Erbes H, et al. ProC Global: the first functional screening assay for the complete protein C pathway. Clin Chem 1997; 43: 1719-23.
11. Tripodi A, Akhavan S, Asti D, et al. Laboratory screening of thrombophilia. Evaluation of the diagnostic efficacy of a global test to detect congenital deficiencies of the protein C anticoagulant pathway. Blood Coagul Fibrinolysis 1998; 9: 485-9.
12. Grand'Maison A, Bates SM, Johnston M, et al. "ProC Global": a functional screening test that predicts recurrent venous thromboembolism. Thromb Haemost 2005;93:600-4.
13. Endrikat J, Noah K Gerlinger C, et al. Impact of oral contraceptive use on APC-resistance: a prospective, randomized clinical trial with three low-dose preparations. Contraception 2001; 64: 217-22.
14. Wu O, Robertson L, Twaddle S, et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 2006;10:1-110.
15. Galit S, Aberbach I, Schliamser L, et al. Evaluation of ProC Global assay in women with a history of VTE on hormonal therapy. Thromb Haemost 20061- 96: 578-83.